A US court has awarded a UK pension fund the right to lead a class action against pharmaceutical giant GlaxoSmithKline (GSK), in one of the first appointments of its kind.

Avon Pension Fund will be represented by US securities firm Coughlin Stoia Gellern Rudman & Robbins as it seeks $2.7m (£1.3m) in damages after alleging that GSK misled investors over the safety of diabetes drug Avandia.